Cost–effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016).
  MedlineGoogle Scholar
• 2. Hwang S-Y, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol. Therapeut. 199, 30–57 (2019).
  Medline CASGoogle Scholar
• 3. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9(2), 176–198 (2019).
  Medline CASGoogle Scholar
• 4. Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 17(1), 1–9 (2019).
  MedlineGoogle Scholar
• 5. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl. J. Med. 379(22), 2108–2121 (2018).
  Medline CASGoogle Scholar
• 6. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. www.nccn.org/patients
  Google Scholar
• 7. Durkee BY, Qian Y, Pollom EL et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 34(9), 902–909 (2016).
  Medline CASGoogle Scholar
• 8. Hoyle Mw HW. Improved curve fits to summary survival data: application to economic evaluation of health technologies. Bmc Med. Res. Methodol. 11, 139 (2011).
  MedlineGoogle Scholar
• 9. Wan XM, Peng LB, Ma JA, Li YJ. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer 123(14), 2634–2641 (2017).
  Medline CASGoogle Scholar
• 10. Elizabeth Arias PD, Melonie Heron, Jiaquan Xu. United States Life Tables, 2014. National Vital Statistics Reports 66(NO.4), (2017). www.cdc.gov/nchs/products/nvsr.htm
  Google Scholar
• 11. Centers for Medicare and Medicaid Services: Medicare Part B Drug Average Sale Price. www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles
  Google Scholar
• 12. Flatiron Health. https://flatiron.com/
  Google Scholar
• 13. Centers for Medicare and Medicaid Services: Medicare Physician Fee Schedule 2014. www.cms.gov/apps/physician-fee-schedule/
  Google Scholar
• 14. The Consumer Price Index (US Bureau of Labor Statistics). www.bls.gov/data/inflation_calculator.htm
  Google Scholar
• 15. Blackley EF, Loi S. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Breast 48(Suppl. 1), S44–S48 (2019).
  MedlineGoogle Scholar
• 16. Husereau D, Drummond M, Petrou S et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16(2), 231–250 (2013).
  MedlineGoogle Scholar
• 17. Briggs AH, Weinstein MC, Fenwick EA et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med. Decis. Making 32(5), 722–732 (2012).
  MedlineGoogle Scholar
• 18. Zhou K, Zhou J, Huang J et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer 130, 1–4 (2019).
  MedlineGoogle Scholar
• 19. Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: a United States–based cost-effectiveness analysis. Cancer 125(20), 3526–3534 (2019).
  Medline CASGoogle Scholar
• 20. Tosteson Ana SN, Fryback Dg et al. Cost-effectiveness of digital mammography breast cancer screening. Ann. Intern. Med. 148(1), 1–10 (2008).
  MedlineGoogle Scholar
• 21. Luhn P, Chui SY, Hsieh AF et al. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. J. Comp. Eff. Res. doi:10.2217/cer-2019-0077 (2019) (Epub ahead of print).
  MedlineGoogle Scholar
• 22. Cortés J, André F, Gonçalves A et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 15(17), 1951–1961 (2019).
  CASGoogle Scholar
• 23. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br. J. Cancer 95 683–690 (2006).
  Medline CASGoogle Scholar
• 24. Attard CL, Brown S, Alloul K, Moore MJ. Cost–effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Curr. Oncol. 21, e41 (2013).
  Google Scholar